Table 1.
Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | p-trend across quartiles | |
---|---|---|---|---|---|
< 5.2 | 5.2 – 11.0 | 11.1–18.8 | > 18.8 | ||
(n=214) | (n=214) | (n=214) | (n=213) | ||
Age, years | 68.3 ± 6.3 | 68.8 ± 6.3 | 68.9 ± 6.5 | 69.2 ± 6.3 | 0.004 |
Race-ethnicity, n (%) | <0.001 | ||||
White Non-Hispanic | 169 (79.0) | 180 (84.1) | 189 (88.3) | 193 (90.6) | |
Black | 26 (12.5) | 19 (8.9) | 14 (6.5) | 10 (4.7) | |
Other | 19 (8.5) | 15 (7.0) | 11 (5.2) | 10 (4.7) | |
Smoking Status, n (%) | 0.03 | ||||
Never | 123 (58.6) | 123 (57.5) | 120 (56.6) | 99 (47.1) | |
Former | 83 (39.5) | 80 (37.4) | 84 (39.6) | 102 (48.6) | |
Current | 4 (1.9) | 11 (5.1) | 8 (3.8) | 9 (4.3) | |
Education, n (%) | 0.37 | ||||
≤ High school | 71 (33.5) | 78 (36.6) | 74 (34.6) | 63 (29.6) | |
Some college/post secondary training | 59 (27.8) | 56 (26.3) | 48 (22.43) | 67 (31.5) | |
College graduate or higher | 82 (36.7) | 79 (37.1) | 92 (43.0) | 83 (39.0) | |
Income, n (%) | 0.87 | ||||
<$35,000 | 99 (50.0) | 107 (53.8) | 94 (48.0) | 90 (46.9) | |
$35,000–$49,999 | 28 (14.1) | 36 (18.1) | 40 (21.4) | 44 (22.9) | |
≥$50,000 | 71 (35.9) | 56 (28.1) | 62 (31.6) | 58 (30.2) | |
Hormone Use, n (%) | 0.86 | ||||
Never | 95 (44.4) | 98 (45.8) | 91 (42.5) | 96 (45.1) | |
Past | 33 (15.4) | 31 (14.5) | 38 (17.8) | 49 (23.0) | |
Current | 86 (40.2) | 85 (39.7) | 85 (39.7) | 68 (31.9) | |
Current Antihypertensive Medication Use, n (%) | 93 (43.5) | 62 (29.0) | 74 (34.6) | 62 (29.1) | <0.001 |
Current Lipid-Lowering Medication Use, n (%) | 39 (18.4) | 28 (13.2) | 44 (20.9) | 23 (11.4) | 0.04 |
Diabetes, n (%) | 27 (12.6) | 19 (8.9) | 14 (6.5) | 9 (4.3) | <0.001 |
Systolic Blood Pressure, mmHg | 132.0 ± 17.7 | 128.5 ± 17.5 | 128.2 ± 17.4 | 130.7 ± 19.2 | 0.37 |
Diastolic Blood Pressure, mmHg | 75.3 ± 9.8 | 72.5 ± 9.1 | 74.0 ± 9.2 | 74.2 ± 9.7 | 0.32 |
Hypertension | 113 (53.1) | 76 (35.9) | 90 (42.3) | 87 (41.8) | 0.06 |
Total Cholesterol, mg/dL† | 232.1 ± 38.7 | 230.2 ± 38.2 | 233.7 ± 38.8 | 229.0 ± 39.2 | 0.83 |
Triglycerides, mg/dL * ‡ | 156 (100) | 146.5 (91) | 143 (83) | 119 (73) | <0.001 |
HDL Cholesterol, mg/dL † | 56.7 ± 15.3 | 57.2 ± 14.9 | 60.0 ± 16.8 | 66.5 ± 17.0 | <0.001 |
LDL Cholesterol, mg/dL † | 141.5 ± 35.5 | 140.1 ± 35.1 | 142.5 ± 37.7 | 134.8 ± 38.8 | 0.07 |
Aspirin use, n (%) | 60 (28.0) | 58 (27.1) | 51 (23.8) | 42 (19.7) | 0.28 |
Glucose, mg/dL * | 97 (15) | 95 (12) | 95 (13) | 95 (13) | <0.001 |
Insulin, uIu/mL * | 7.2 (7.2) | 6 (6) | 6 (4.9) | 4.5 (4.3) | 0.001 |
HOMA * | 1.8 (2.0) | 1.5 (1.6) | 1.4 (1.3) | 1.1 (1.1) | 0.04 |
C-reactive protein, mg/mL * | 3.3 (4.9) | 2.6 (4.3) | 2.4 (3.8) | 1.9 (3.4) | <0.001 |
BMI, kg/m2 | 27.9 ± 5.1 | 27.2 ± 5.4 | 26.9 ± 5.3 | 25.8 ± 5.4 | <0.001 |
Waist Circumference, cm | 86.7 ± 12.5 | 85.1 ± 13.0 | 84.7 ± 11.7 | 81.5 ± 11.1 | <0.001 |
BMI groups, n (%) | <0.001 | ||||
Normal weight (BMI < 25) | 66 (31.4) | 78 (37.1) | 87 (40.9) | 111 (52.9) | |
Overweight (25 ≤ BMI < 30) | 87 (41.4) | 80 (38.1) | 78 (36.6) | 67 (31.9) | |
Obese (BMI > 30) | 57 (27.1) | 52 (24.8) | 48 (22.5) | 32 (15.2) | |
Physical Activity, METs per week | 13.4 ± 13.7 | 14.9 ± 15.3 | 15.3 ± 15.0 | 14.1 ± 12.2 | 0.61 |
Median (interquartile range)
To convert mg/dL to mmol/L for cholesterols divide by 38.67
To convert mg/dL to mmol/L for triglycerides divide by 88.57
Values for continuous variables are reported as mean ± SD